Revive Therapeutics Expands Bucillamine's Patent Portfolio in North America

Revive Therapeutics Ltd. has announced significant strides in its intellectual property for the drug bucillamine, targeting chemical warfare and infectious diseases. The company has filed patent applications in North America for bucillamine's use against nerve agents and secured a Canadian patent for its role in combating infectious diseases such as influenza and COVID-19.

These patents solidify Revive's foothold in the medical countermeasures domain, benefiting from government programs focused on emergency preparedness and stockpiling. With the potential to address nerve-agent exposure, bucillamine is seen as a promising platform given its antioxidant capabilities and decades of use in arthritis treatment in Asia.

This strategic expansion not only enhances Revive's patent estate but also supports prospective collaborations, licensing, and development ventures. CEO Michael Frank emphasizes the platform’s growing role in public health and government initiatives, showcasing its versatility beyond a single indication.